175 related articles for article (PubMed ID: 29511346)
1. Gene activation of CEBPA using saRNA: preclinical studies of the first in human saRNA drug candidate for liver cancer.
Reebye V; Huang KW; Lin V; Jarvis S; Cutilas P; Dorman S; Ciriello S; Andrikakou P; Voutila J; Saetrom P; Mintz PJ; Reccia I; Rossi JJ; Huber H; Habib R; Kostomitsopoulos N; Blakey DC; Habib NA
Oncogene; 2018 Jun; 37(24):3216-3228. PubMed ID: 29511346
[TBL] [Abstract][Full Text] [Related]
2. MTL-CEBPA, a Small Activating RNA Therapeutic Upregulating C/EBP-α, in Patients with Advanced Liver Cancer: A First-in-Human, Multicenter, Open-Label, Phase I Trial.
Sarker D; Plummer R; Meyer T; Sodergren MH; Basu B; Chee CE; Huang KW; Palmer DH; Ma YT; Evans TRJ; Spalding DRC; Pai M; Sharma R; Pinato DJ; Spicer J; Hunter S; Kwatra V; Nicholls JP; Collin D; Nutbrown R; Glenny H; Fairbairn S; Reebye V; Voutila J; Dorman S; Andrikakou P; Lloyd P; Felstead S; Vasara J; Habib R; Wood C; Saetrom P; Huber HE; Blakey DC; Rossi JJ; Habib N
Clin Cancer Res; 2020 Aug; 26(15):3936-3946. PubMed ID: 32357963
[TBL] [Abstract][Full Text] [Related]
3. Development of MTL-CEBPA: Small Activating RNA Drug for Hepatocellular Carcinoma.
Setten RL; Lightfoot HL; Habib NA; Rossi JJ
Curr Pharm Biotechnol; 2018; 19(8):611-621. PubMed ID: 29886828
[TBL] [Abstract][Full Text] [Related]
4. Development and Mechanism of Small Activating RNA Targeting CEBPA, a Novel Therapeutic in Clinical Trials for Liver Cancer.
Voutila J; Reebye V; Roberts TC; Protopapa P; Andrikakou P; Blakey DC; Habib R; Huber H; Saetrom P; Rossi JJ; Habib NA
Mol Ther; 2017 Dec; 25(12):2705-2714. PubMed ID: 28882451
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms involved in the activation of C/EBPα by small activating RNA in hepatocellular carcinoma.
Zhao X; Reebye V; Hitchen P; Fan J; Jiang H; Sætrom P; Rossi J; Habib NA; Huang KW
Oncogene; 2019 May; 38(18):3446-3457. PubMed ID: 30643190
[TBL] [Abstract][Full Text] [Related]
6. MTL-CEBPA Combined with Immunotherapy or RFA Enhances Immunological Anti-Tumor Response in Preclinical Models.
Huang KW; Tan CP; Reebye V; Chee CE; Zacharoulis D; Habib R; Blakey DC; Rossi JJ; Habib N; Sodergren MH
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502076
[TBL] [Abstract][Full Text] [Related]
7. Anti-inflammatory Activity of MTL-CEBPA, a Small Activating RNA Drug, in LPS-Stimulated Monocytes and Humanized Mice.
Zhou J; Li H; Xia X; Herrera A; Pollock N; Reebye V; Sodergren MH; Dorman S; Littman BH; Doogan D; Huang KW; Habib R; Blakey D; Habib NA; Rossi JJ
Mol Ther; 2019 May; 27(5):999-1016. PubMed ID: 30852139
[TBL] [Abstract][Full Text] [Related]
8. Upregulation of C/EBPα Inhibits Suppressive Activity of Myeloid Cells and Potentiates Antitumor Response in Mice and Patients with Cancer.
Hashimoto A; Sarker D; Reebye V; Jarvis S; Sodergren MH; Kossenkov A; Sanseviero E; Raulf N; Vasara J; Andrikakou P; Meyer T; Huang KW; Plummer R; Chee CE; Spalding D; Pai M; Khan S; Pinato DJ; Sharma R; Basu B; Palmer D; Ma YT; Evans J; Habib R; Martirosyan A; Elasri N; Reynaud A; Rossi JJ; Cobbold M; Habib NA; Gabrilovich DI
Clin Cancer Res; 2021 Nov; 27(21):5961-5978. PubMed ID: 34407972
[TBL] [Abstract][Full Text] [Related]
9. Novel RNA oligonucleotide improves liver function and inhibits liver carcinogenesis in vivo.
Reebye V; Sætrom P; Mintz PJ; Huang KW; Swiderski P; Peng L; Liu C; Liu X; Lindkaer-Jensen S; Zacharoulis D; Kostomitsopoulos N; Kasahara N; Nicholls JP; Jiao LR; Pai M; Spalding DR; Mizandari M; Chikovani T; Emara MM; Haoudi A; Tomalia DA; Rossi JJ; Habib NA
Hepatology; 2014 Jan; 59(1):216-27. PubMed ID: 23929703
[TBL] [Abstract][Full Text] [Related]
10. RNA Activation-A Novel Approach to Therapeutically Upregulate Gene Transcription.
Tan CP; Sinigaglia L; Gomez V; Nicholls J; Habib NA
Molecules; 2021 Oct; 26(21):. PubMed ID: 34770939
[TBL] [Abstract][Full Text] [Related]
11. Treatment of Liver Cancer by C/EBPA saRNA.
Zhao X; Voutila J; Ghobrial S; Habib NA; Reebye V
Adv Exp Med Biol; 2017; 983():189-194. PubMed ID: 28639200
[TBL] [Abstract][Full Text] [Related]
12. Differentially expressed MicroRNAs provide mechanistic insight into fibrosis-associated liver carcinogenesis in mice.
Marrone AK; Shpyleva S; Chappell G; Tryndyak V; Uehara T; Tsuchiya M; Beland FA; Rusyn I; Pogribny IP
Mol Carcinog; 2016 May; 55(5):808-17. PubMed ID: 25865624
[TBL] [Abstract][Full Text] [Related]
13. Chemerin in a Mouse Model of Non-alcoholic Steatohepatitis and Hepatocarcinogenesis.
Haberl EM; Pohl R; Rein-Fischboeck L; Feder S; Sinal CJ; Buechler C
Anticancer Res; 2018 May; 38(5):2649-2657. PubMed ID: 29715085
[TBL] [Abstract][Full Text] [Related]
14. Hepatocyte-specific CCAAT/enhancer binding protein α restricts liver fibrosis progression.
Yan T; Yan N; Xia Y; Sawaswong V; Zhu X; Dias HB; Aibara D; Takahashi S; Hamada K; Saito Y; Li G; Liu H; Yan H; Velenosi TJ; Krausz KW; Huang J; Kimura S; Rotman Y; Qu A; Hao H; Gonzalez FJ
J Clin Invest; 2024 Apr; 134(7):. PubMed ID: 38557493
[TBL] [Abstract][Full Text] [Related]
15. Attenuation of steatohepatitis, fibrosis, and carcinogenesis in mice fed a methionine-choline deficient diet by CCAAT/enhancer-binding protein homologous protein deficiency.
Toriguchi K; Hatano E; Tanabe K; Takemoto K; Nakamura K; Koyama Y; Seo S; Taura K; Uemoto S
J Gastroenterol Hepatol; 2014 May; 29(5):1109-18. PubMed ID: 24329600
[TBL] [Abstract][Full Text] [Related]
16. Hepatic transforming growth factor beta gives rise to tumor-initiating cells and promotes liver cancer development.
Wu K; Ding J; Chen C; Sun W; Ning BF; Wen W; Huang L; Han T; Yang W; Wang C; Li Z; Wu MC; Feng GS; Xie WF; Wang HY
Hepatology; 2012 Dec; 56(6):2255-67. PubMed ID: 22898879
[TBL] [Abstract][Full Text] [Related]
17. C/EBPalpha is up-regulated in a subset of hepatocellular carcinomas and plays a role in cell growth and proliferation.
Lu GD; Leung CH; Yan B; Tan CM; Low SY; Aung MO; Salto-Tellez M; Lim SG; Hooi SC
Gastroenterology; 2010 Aug; 139(2):632-43, 643.e1-4. PubMed ID: 20347819
[TBL] [Abstract][Full Text] [Related]
18. Fasting inhibits hepatic stellate cells activation and potentiates anti-cancer activity of Sorafenib in hepatocellular cancer cells.
Lo Re O; Panebianco C; Porto S; Cervi C; Rappa F; Di Biase S; Caraglia M; Pazienza V; Vinciguerra M
J Cell Physiol; 2018 Feb; 233(2):1202-1212. PubMed ID: 28471474
[TBL] [Abstract][Full Text] [Related]
19. Gene transfer and therapy with adenoviral vector in rats with diethylnitrosamine-induced hepatocellular carcinoma.
Qian C; Idoate M; Bilbao R; Sangro B; Bruña O; Vázquez J; Prieto J
Hum Gene Ther; 1997 Feb; 8(3):349-58. PubMed ID: 9048202
[TBL] [Abstract][Full Text] [Related]
20. Hepatic inflammation-fibrosis-cancer axis in the rat hepatocellular carcinoma induced by diethylnitrosamine.
Ding YF; Wu ZH; Wei YJ; Shu L; Peng YR
J Cancer Res Clin Oncol; 2017 May; 143(5):821-834. PubMed ID: 28238064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
